Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708451 | 0.86 | SLC6A4 (0.51) | CES2CES1SLC6A4SLC6A3TSHR | |
| SCHEMBL30301996 | 0.86 | SLC6A4 (0.51) | CES2CES1SLC6A4SLC6A3TSHR | |
| SCHEMBL14012584 | 0.84 | CES2 (0.61) | CES2CES1SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL523258 | 0.84 | CES2 (0.61) | CES2CES1SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL1462096 | 0.82 | ABL1 (0.61) | SLC6A4SLC6A3TSHRALDH1A1HPGD | |
| SCHEMBL2060214 | 0.82 | CYP46A1 (0.53) | TSHRALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL31258832 | 0.82 | CA12 (0.67) | SLC6A4SLC6A3TSHRALDH1A1HSD17B10 | |
| SCHEMBL1367028 | 0.82 | CA12 (0.67) | SLC6A4SLC6A3TSHRALDH1A1HSD17B10 | |
| SCHEMBL1977659 | 0.82 | SLC6A4 (0.49) | CES2CES1SLC6A4SLC6A3TSHR | |
| SCHEMBL1401556 | 0.82 | KDM4E (0.58) | ALDH1A1HPGDHSD17B10SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163445-B | Larotinib intermediate and preparation method thereof | 重庆医科大学 | 2023-06-20 | — | — | CN | claimed |
| CN-113321800-B | Application of selective laser sintering by taking polyether-ether-ketone prepared from tetramethyl guanidine tetrafluoroborate as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113429532-B | Application of polyether-ether-ketone prepared from 1-butyl-3-methylimidazole bromide in selective laser sintering | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113429562-B | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113429563-B | Application of selective laser sintering by taking polyether-ether-ketone prepared by solvent as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-114163445-A | Raatinib intermediate and preparation method thereof | 重庆医科大学 | 2022-03-11 | — | — | CN | claimed |
| CN-113429562-A | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113429532-A | Application of selective laser sintering by using polyether-ether-ketone prepared from 1-butyl-3-methylimidazole bromine salt as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113429563-A | Application of selective laser sintering by using polyether-ether-ketone prepared by adopting solvent as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113321800-A | Application of selective laser sintering by using polyether-ether-ketone prepared from tetramethylguanidine tetrafluoroborate as raw material | 江汉大学 | 2021-08-31 | — | — | CN | claimed |
| CN-108034047-B | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2021-06-22 | — | — | CN | claimed |
| CN-105732605-A | Preparation method of isavuconazole intermediate | 山东亨利医药科技有限责任公司 | 2016-07-06 | — | — | CN | claimed |
| CN-102131791-B | Dibenzothiepiazane derivatives and their use | ASTRAZENECA SWEDEN AB | 2014-12-24 | — | — | CN | claimed |
| US-8653257-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2012-08-09 | — | — | US | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | CES2 866/4885CES1 105/4885SLC6A4 1617/4885 |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | DRD4, DRD2, GABBR1 | CES2 2550/4885CES1 4544/4885SLC6A4 30/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CES2 2503/4885CES1 834/4885SLC6A4 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.